canertinib dihydrochloride

01/01/2002 - "Due to the preclinical activity of CI-980 and its similar mechanism of action to drugs effective in small cell lung cancer, a phase II trial in extensive small cell lung cancer was initiated by The Ohio State University Phase II Research Consortium. "
01/01/2002 - "We conclude that despite antitumor activity demonstrated in preclinical studies, CI-980 does not have biological activity in previously untreated small cell lung cancer at this dose and infusion protocol."
01/01/2002 - "A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study."

01/01/2002 - "The purpose of this phase I/II trial was to determine the maximal tolerated dose of CI-980, and determine efficacy against malignant glioma. "
01/01/2002 - "These results fail to demonstrate the significant activity of CI-980 against recurrent glioma."
01/01/2002 - "CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980."

11/01/1999 - "Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study."
03/01/1997 - "In a Phase I and pharmacological study, 16 patients with advanced solid neoplasms were treated with CI-980 on a continuous 72-h infusion schedule at doses ranging from 3.0-5.4 mg/m2/day every 3 weeks. "
01/01/1997 - "A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors."
11/01/1999 - "CI-980 showed preliminary evidence of activity in recurrent pediatric malignancies, with tolerable, reversible toxicities."
01/01/2002 - "In preclinical tumor models, CI-980 showed a broad spectrum of activity, including in multi-drug resistant tumor cell lines, with activity at least equal to that of vincristine. "

01/01/2001 - "CI-980 administered at this dose and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further investigation."
01/01/2001 - "Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. "
05/01/2000 - "CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer."
05/01/2000 - "CI-980 in advanced melanoma and hormone refractory prostate cancer."

12/01/1997 - "At the stated dose and schedule, CI-980 lacks activity in metastatic colorectal carcinoma. "
12/01/1997 - "Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. "